Biotech Values

[ghmm]

iwfal,
I suspect you may have a good point on ALTH. On Epix I think it was a bit trickier. If memory serves they not only met their end-point but were told not 1 but perhaps 2 additional trials would be required. I think they were pretty much up against a wall at that point and not in a position to do those trials especially with a moving target (how Michael Astrue characterized the end point/FDA requirement).

dewophile looks like you may have picked this well! I was not familiar enough with the company to do what you did though it seemed logical. They have a lymphoma drug that I had noticed a while back and that is what got me interested in following them (just a bit though).